Lung cancer remains one of the most aggressive and deadly cancers, affecting over 200,000 Americans each year. Despite available treatments, approximately one in three patients will experience tumor recurrence, with a median survival of less than a year following diagnosis. Lung cancer’s rapid growth, tendency to spread, and high resistance to conventional therapies contribute to its poor prognosis and high mortality rate.
A major challenge in treating lung cancer effectively is its population of cancer stem cells. These resilient cells are responsible for the cancer’s ability to resist treatment and recur, allowing the tumor to regenerate after conventional therapies.
At Acomhal Research, we are working to advance cancer care by developing pioneering therapies aimed at addressing the significant challenges posed by aggressive cancers, including lung cancer, with our innovative drug, a mimetic peptide based on a segment of Cx43, a protein essential for cell-to-cell communication.
